Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted by its Compensation Committee on October 6, 2025 to 21 new employees under the 2024 Inducement Plan.

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted by its Compensation Committee on October 6, 2025 to 21 new employees under the 2024 Inducement Plan.

The grants consist of 135,100 non‑qualified stock options and 70,775 restricted stock units (RSUs). Each option has an exercise price of $30.94, equal to Vera Therapeutics’ closing price on October 6, 2025. Options vest over four years with 25% after one year and monthly vesting over the following 36 months. RSUs vest 25% on each anniversary beginning November 20, 2025, over four years. Awards are subject to the Inducement Plan and individual award agreements and to continued service through vesting dates.

Argus Oct 13 session

+1.33% close to close Open Argus

Details

News Market Reaction – VERA

On Oct 13, the first trading day after this news, VERA closed 1.33% above the previous close.

Data tracked by StockTitan Argus for the Oct 13 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 135,100 shares of Class A common stock and restricted stock units (RSUs) underlying 70,775 shares of Class A common stock to twenty-one (21) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on October 6, 2025 has an exercise price per share equal to $30.94, Vera Therapeutics’ closing trading price on October 6, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, 2025, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. In addition, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera Therapeutics also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera Therapeutics retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Vera Therapeutics (VERA) grant on October 6, 2025?

Vera granted 135,100 non‑qualified stock options and 70,775 RSUs to 21 new employees under its 2024 Inducement Plan.

What is the exercise price of the stock options granted by VERA on October 6, 2025?

Each option has an exercise price of $30.94, equal to Vera Therapeutics’ closing price on October 6, 2025.

What are the vesting terms for VERA's October 6, 2025 option grants?

Options vest over four years: 25% after one year and the remaining shares vest monthly over the next 36 months, subject to continued service.

When do the RSUs granted by Vera Therapeutics begin vesting?

Each RSU award vests over four years with 25% vesting on each anniversary starting November 20, 2025, subject to continued service.

How many employees received inducement awards from VERA on October 6, 2025?

A total of 21 new employees received inducement awards on October 6, 2025.

Under what authority were VERA's inducement awards approved?

The Compensation Committee approved the awards as inducements under Nasdaq Listing Rule 5635(c)(4) and the company's 2024 Inducement Plan.